Login
$ELVN
$47.62 -$1.18 (2.42%) Live

$ELVN 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial

14 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness

05 Aug 2026 8-K: Results of Operations and Financial Condition

Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile

12 Jun 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Enliven Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”), (i) an aggregate of 8,933,334 shares of its common stock, par value $0.0...

11 Jun 2026 8-K: Regulation FD Disclosure; Other Events

Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components

10 Jun 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Enliven Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY:

07 May 2026 8-K: Results of Operations and Financial Condition

Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026

03 Mar 2026 8-K: Results of Operations and Financial Condition

Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026

07 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation

Scott Garland, a seasoned biopharma executive with a strong track record of leading successful

11 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

1. Purpose. The purpose of this 2025 Inducement Equity Incentive Plan (the “Plan”) of Enliven Therapeutics, Inc., a Delaware corporation (the “Company”), is to attract and retain the best available personnel for positions of substantial ...

12 Nov 2025 8-K: Results of Operations and Financial Condition

Completed enrollment of the randomized Phase 1b cohorts of the ongoing ENABLE trial of ELVN-001 in CML

13 Aug 2025 8-K: Results of Operations and Financial Condition

Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks and demonstrating a favorable safety and tolerability profile across all do...

25 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

Enliven Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 24, 2025. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below.

16 Jun 2025 8-K: Entry into a Material Definitive Agreement; Other Events

Enliven Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”), (i) an aggregate of 8,394,737 shares of its common stock, par value $0.0...

13 Jun 2025 8-K: Regulation FD Disclosure; Other Events

Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving

14 May 2025 8-K: Results of Operations and Financial Condition

Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June

13 Mar 2025 8-K: Results of Operations and Financial Condition

Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues

13 Nov 2024 8-K: Results of Operations and Financial Condition

Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks and showing that ELVN-001 remains well-tolerated with no dose reductions

13 Aug 2024 8-K: Results of Operations and Financial Condition

Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML that is relapsed, refractory or intolerant to available TKIs

18 Jun 2024 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

1. Purpose. The purpose of this Amended and Restated 2020 Equity Incentive Plan (the “Plan”) of Enliven Therapeutics, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing th...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support